<SEC-DOCUMENT>0001628280-25-025486.txt : 20250514
<SEC-HEADER>0001628280-25-025486.hdr.sgml : 20250514
<ACCEPTANCE-DATETIME>20250514160818
ACCESSION NUMBER:		0001628280-25-025486
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250514
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250514
DATE AS OF CHANGE:		20250514

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adverum Biotechnologies, Inc.
		CENTRAL INDEX KEY:			0001501756
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				205258327
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36579
		FILM NUMBER:		25945478

	BUSINESS ADDRESS:	
		STREET 1:		100 CARDINAL WAY
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		(650) 649-1004

	MAIL ADDRESS:	
		STREET 1:		100 CARDINAL WAY
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Avalanche Biotechnologies, Inc.
		DATE OF NAME CHANGE:	20100921
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>advm-20250514.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:82c4ac68-4dc2-46d6-a6c7-b559c0721b8f,g:d454b1ec-48f6-4fef-9453-5a15e1b23d20,d:7ac0d3ccc67f40c78149462d8d8f6b99-->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>advm-20250514</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-21">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001501756</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="advm-20250514.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-14</xbrli:startDate><xbrli:endDate>2025-05-14</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i7ac0d3ccc67f40c78149462d8d8f6b99_1"></div><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.438%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.438%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">May 14, 2025</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.586%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Adverum Biotechnologies, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.438%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.296%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-36579</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">20-5258327</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">100 Cardinal Way</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Redwood City</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-9">CA</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">94063</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">656-9323</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.438%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a&#8211;12 under the Exchange Act (17 CFR 240.14a&#8211;12)</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d&#8211;2(b) under the Exchange Act (17 CFR 240.14d&#8211;2(b))</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e&#8211;4(c) under the Exchange Act (17 CFR 240.13e&#8211;4(c))</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange<br/>on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">ADVM</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></div><div style="margin-bottom:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i7ac0d3ccc67f40c78149462d8d8f6b99_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 2.02&#160;&#160;&#160;&#160;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Results of Operations and Financial Condition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">On </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-23">May&#160;14, 2025</ix:nonNumeric></span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Adverum Biotechnologies, Inc. issued a press release announcing its financial results for the quarter ended March&#160;31, 2025, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The information in this report, including the exhibit hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Adverum Biotechnologies, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></div><div id="i7ac0d3ccc67f40c78149462d8d8f6b99_10"></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.196%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit991_51425pressrelea.htm">Press Release dated May 14, 2025, announcing Adverum Biotechnologies, Inc. financial results for the quarter ended </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit991_51425pressrelea.htm">March</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit991_51425pressrelea.htm"> 31, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit991_51425pressrelea.htm">5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit991_51425pressrelea.htm">, and providing a corporate update.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The cover page of this report has been formatted in Inline XBRL.</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i7ac0d3ccc67f40c78149462d8d8f6b99_13"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.397%"><tr><td style="width:1.0%"/><td style="width:47.108%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.178%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Adverum Biotechnologies, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-24">May&#160;14, 2025</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">/s/ Laurent Fischer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Laurent Fischer, M.D. <br/>President and Chief Executive Officer</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991_51425pressrelea.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i9d2e54835bfd4b50af5112f4b21517db_1"></div><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div><img alt="logoa.jpg" src="logoa.jpg" style="height:58px;margin-bottom:5pt;vertical-align:text-bottom;width:182px"></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:107%">Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:107%;padding-left:12.53pt">Initiated ARTEMIS, the first-ever registrational intravitreal gene therapy trial, in both treatment-experienced and treatment-naive patients with wet AMD</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:107%;padding-left:12.53pt">Presented the first human data mapping cell-level transduction and aflibercept mRNA expression 3.5 years after Ixo-vec administration, establishing the potential for life-long vision preservation </font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">REDWOOD CITY, Calif., May&#160;14, 2025 -- </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Adverum Biotechnologies, Inc. (Nasdaq&#58; ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly prevalent ocular diseases, today reported financial results for the first quarter of 2025. The company also provided pipeline highlights and anticipated milestones.</font></div><div><font style="color:#000000;font-family:'null',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We&#8217;ve kicked off 2025 with strong execution by initiating ARTEMIS, our first pivotal trial for Ixo-vec, and are thrilled with the enthusiasm of retina specialists and patient interest. We look forward to starting our second registrational study, AQUARIUS, later this year,&#8221; stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies. &#8220;The long-term data from OPTIC and LUNA, along with the anticipated two-year follow-up data from LUNA, bolster confidence in Ixo-vec's potential to provide One And Done&#8482; life-long injection-free vision preservation for  wet AMD patients. Additionally, new data presented at ARVO showcase the first human cell-level mapping of Ixo-vec transduction and aflibercept mRNA expression, supporting its differentiated clinical profile. Ixo-vec has demonstrated robust retinal transduction and sustained therapeutic levels, establishing a product profile that was overwhelmingly preferred by LUNA patients over their previous frequent anti-VEGF injections. If approved, Ixo-vec may ensure continued anti-VEGF protection for the many wet AMD patients who are lost to follow-up within just 2 to 3 years, and we expect that it will offer a compelling value proposition for retina practices.</font><font style="color:#000000;font-family:'null',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;</font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Ixo-vec Recent Program Highlights</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Initiated ARTEMIS, the first-ever registrational intravitreal gene therapy trial in patients with wet AMD</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">ARTEMIS continues to enroll both treatment-experienced and treatment-na&#239;ve patients.  </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">ARTEMIS is a US-based study evaluating a single administration of Ixo-vec (6E10 vg&#47;eye) compared to on-label aflibercept (2mg) every 8 weeks in approximately 284 patients with wet AMD.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">ARTEMIS is the first of two planned Phase 3 registrational trials to evaluate Ixo-vec in patients with wet AMD.  Details on the second study, AQUARIUS, are forthcoming.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Presented Ixo-vec biodistribution data from an OPTIC participant&#8217;s donated eye at ARVO 2025</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'null',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">In Situ Hybridization Demonstrates Ocular Distribution of Ixo-vec IVT Gene Therapy in Human Cadaver Eye with wAMD and Supports Durable Clinical Efficacy</font><font style="color:#000000;font-family:'null',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> was presented in a Poster Presentation on May 7</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, 2025, at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting. </font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">In the 6 years prior to receiving Ixo-vec, the patient received 36 anti-VEGF injections, including 11 injections in the past year alone. Notably, after a single injection of Ixo-vec, the patient exhibited a robust clinical response, demonstrated by maintenance of visual acuity and sustained fluid control, with only a single supplemental injection administered after more than 3.5 years of follow-up and shortly before death.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">This analysis represents the first human intraocular cell-level mapping of vector transduction and transgenic aflibercept expression following IVT gene therapy. Ixo-vec drove the most prominent expression of aflibercept in the macula and peripheral retina. The sustained presence of Ixo-vec vector DNA and aflibercept mRNA correlates with the observed durable suppression of fluid and maintained visual acuity in the patient and supports the years of, and potentially lifelong, clinical activity observed in OPTIC and LUNA. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">New publication supports best-in-class transduction efficiency of AAV.7m8 capsid</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Data further validates Adverum&#8217;s 7m8 capsid and molecular mechanism underpinning the potential best-in-class profile of maintained visual and anatomic outcomes and associated injection-freedom from the OPTIC and LUNA studies. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Naturally occurring AAVs exhibit suboptimal transduction efficiency in certain cells, including the retina. 7m8 is derived from the natural AAV2 serotype by directed evolution in multiple species.  AAV2 variants were screened for increased transduction following IVT administration. An engineered 10-amino acid peptide loop enables 7m8 to cross the inner limiting membrane and thus transduce the retina, generating strong transgene expression. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">The paper, &#8220;Advances in AAV Capsid Engineering&#58; Integrating Rational Design, Directed Evolution and Machine Learning&#8221;, was published in the journal Molecular Therapy. The findings reinforce the robust retinal transduction and expression profile of 7m8, demonstrating a 5-fold increase in transduction efficiency of retinal cells compared with natural AAV2 and increased transduction efficiency compared to other engineered AAV capsids.  </font></div><div style="margin-bottom:6pt;margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Upcoming Anticipated Milestones</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">2H 2025 &#160;&#160;&#160;&#160;Initiate the global AQUARIUS Phase 3 trial</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">4Q 2025 &#160;&#160;&#160;&#160;Present Phase 2 LUNA two-year long-term follow-up data</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Financial Results for the Three Months Ended March 31, 2025</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Cash, cash equivalents and short-term investments</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8239;were $83.1 million as of March 31, 2025, compared to $125.7 million as of December 31, 2024. Adverum expects its cash, cash equivalents and short-term investments to fund operations into the second half of 2025. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Research and development expenses </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">were $28.7 million for the three months ended March 31, 2025, compared to $15.4 million for the same period in 2024. Research and development expenses increased due to higher material production and bioanalytics expenses, higher clinical trial expense, higher personnel related costs, and higher consultants and contractor expenses, all driven by the Phase 3 clinical trial. Stock-based compensation expense included in research and development expenses was $1.2 million for the first quarter of 2025.</font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">General and administrative expenses </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">were $19.5 million for the three months ended March 31, 2025, compared to $13.8 million for the same period in 2024. General and administrative expenses were higher due to higher facilities expenses driven by payment to discharge a lien on the North Carolina premises, higher professional services expenses, and higher consultant and contractor expenses&#59; partially offset by lower personnel related costs. Stock-based compensation expense included in general and administrative expenses was $1.6 million for the first quarter of 2025.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Net loss</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> was $47.0 million, or $2.25 per basic and diluted share, for the three months ended March 31, 2025, compared to $27.1 million, or $1.65 per basic and diluted share for the same period in 2024. </font></div><div style="margin-bottom:6pt;margin-top:6pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Ixo-vec in Wet AMD</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Adverum is developing ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), its clinical-stage gene therapy product candidate, for the treatment of wet AMD. Ixo-vec utilizes a proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. Unlike other ophthalmic gene therapies that require surgery to administer the gene therapy under the retina (sub-retinal approach), Ixo-vec is designed to be administered as a one-time IVT injection in the physician&#8217;s office, deliver long-term efficacy, reduce the burden of frequent anti-VEGF, optimize patient compliance and improve vision outcomes for patients with wet AMD. In recognition of the need for new treatment options for wet AMD, FDA granted Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations for Ixo-vec for the treatment of wet AMD. Ixo-vec has also received PRIME designation from the EMA and the Innovation Passport from the United Kingdom&#8217;s Medicines and Healthcare Products Regulatory Agency for the treatment of wet AMD. </font></div><div style="margin-bottom:6pt;margin-top:6pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Adverum Biotechnologies</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Adverum Biotechnologies (NASDAQ&#58; ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians&#8217; offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">www.adverum.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font><br></font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-looking Statements</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Statements contained in this press release regarding events or results that may occur in the future are </font><font style="color:#000000;font-family:'null',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">forward-looking statements</font><font style="color:#000000;font-family:'null',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements regarding&#58;  the therapeutic and commercial potential of Ixo-vec, including its potential to preserve sight for life in highly prevalent ocular diseases and provide One-And-Done life-long injection-free vision preservation for wet AMD patients &#59; the potential to reduce the burden of frequent anti-VEGF and optimize patient compliance&#59; the potential best-in-class product profile of Ixo-vec&#59; plans and milestones related to Adverum&#8217;s product candidates, including the planned initiation of the global AQUARIUS Phase 3 trial and the presentation of LUNA Phase 2 two-year long-term follow-up data&#59; Adverum&#8217;s cash sufficiency and runway and other statements that are not a historical fact. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including risks inherent to, without limitation&#58; Adverum&#8217;s novel technology, which makes it difficult to predict the timing of commencement and completion of clinical trials&#59; regulatory uncertainties&#59; enrollment uncertainties&#59; the results of early clinical trials not always being predictive of future clinical trials and results&#59; the potential for future complications or side effects in connection with use of Ixo-vec&#59; Adverum&#8217;s ability to continue as a going concern and improve its financial position&#59; and risks associated with market conditions. Additional risks and uncertainties facing Adverum are set forth under the caption </font><font style="color:#000000;font-family:'null',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Risk Factors</font><font style="color:#000000;font-family:'null',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and elsewhere in Adverum&#8217;s Securities and Exchange Commission (SEC) filings and reports, including Adverum&#8217;s most recent Annual Report on Form 10&#8209;K filed with the SEC on April 15, 2025 and subsequent filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Adverum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. </font></div><div style="margin-bottom:6pt;margin-top:6pt"><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Corporate &#38; Investor Inquiries&#58;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Adverum Investor Relations</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Email&#58; </font><font style="color:#3051f2;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ir&#64;adverum.com</font></div><div><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Media&#58;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Jason Awe, Ph.D.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Executive Director, Corporate Communications</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Email&#58; </font><font style="color:#3051f2;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">jawe&#64;adverum.com</font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.235%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Adverum Biotechnologies, Inc.</font></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Selected Consolidated Balance Sheet Data</font></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">(In thousands)</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">March 31,</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">December 31,</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2024</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">(Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">(1)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash and cash equivalents, and marketable securities</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">83,083&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">125,691&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total assets</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">137,654&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">179,841&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total current liabilities</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">25,094&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">22,898&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total stockholders' equity</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">26,422&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">70,714&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">(1) Derived from Adverum&#8217;s annual audited consolidated financial statements.</font></td></tr></table></div><div><font><br></font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:61.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:16.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.077%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Adverum Biotechnologies, Inc.</font></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Condensed Consolidated Statements of Operations</font></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">(In thousands except per share data)</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Three months ended March 31,</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2025</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2024</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">(Unaudited)</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operating expenses&#58;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">28,747&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">15,410&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">General and administrative</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">19,474&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">13,789&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total operating expenses</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">48,221&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">29,199&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operating loss</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(48,221)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(29,199)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other income, net</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,202&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2,052&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net loss</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(47,019)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(27,147)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net loss per share &#8212; basic and diluted</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2.25)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1.65)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Weighted-average common shares outstanding - basic and diluted</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">20,938</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">16,479</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="15" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>advm-20250514.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:82c4ac68-4dc2-46d6-a6c7-b559c0721b8f,g:d454b1ec-48f6-4fef-9453-5a15e1b23d20-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:advm="http://www.adverum.com/20250514" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.adverum.com/20250514">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20250514_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20250514_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.adverum.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>advm-20250514_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:82c4ac68-4dc2-46d6-a6c7-b559c0721b8f,g:d454b1ec-48f6-4fef-9453-5a15e1b23d20-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_bb1426ec-500b-4832-a678-382d8e0baeaf_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_a604a917-c351-48c5-b18d-81ee35dff9fa_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_43feb93b-7b17-43bd-a484-1d4e3ada3b5a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_47e7fac5-5394-4f6d-9e9d-4a72a77ad6a4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_1cd87a17-b4bd-4579-a8d7-740c16844705_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_844b12cc-03c8-41e8-9a16-18161c8a4607_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_03fc31d5-cf12-4a69-a15d-f94b17d23de2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_dc8143a9-62bb-4731-9c9b-3bef06ec2c38_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_25c467e5-41f0-449f-b6cc-de0d1961ac80_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_60068dd0-b0ea-41e3-b7d0-6ca3e646e334_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_d8f18e9e-a52d-4f91-bdd9-0648277a2df1_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_bc8e31d1-709d-4185-85ba-3868947e2d57_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_6bd93e07-472a-446a-8bca-1429f19a7249_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_67db8f2c-5fe7-41ed-8253-780da7c191a4_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_5d8a7c9f-e51a-4b59-b8ba-1addd4352ac6_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_6a4d51b3-ead5-40db-b18e-c5c5c71ff7c6_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a95dab82-7fc7-413c-9ab9-885b1b4f639a_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_173b6992-6baa-4f34-ab84-3b61b128fb65_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f128f576-9969-41d3-a7f6-29b02499c8a4_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_45f0a448-e6d2-47d6-a91a-8c573865edc7_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_e1b7436e-1b6f-451d-acc7-11538b12e3e9_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_a24f7df6-456c-4b82-8a1c-42dcd8cf2630_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>advm-20250514_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:82c4ac68-4dc2-46d6-a6c7-b559c0721b8f,g:d454b1ec-48f6-4fef-9453-5a15e1b23d20-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.adverum.com/role/Cover" xlink:type="simple" xlink:href="advm-20250514.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_70e41c6c-71ac-42d7-9f78-0492661407f5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_3d8232e3-d5f0-4065-9c98-946e7f91df8a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_70e41c6c-71ac-42d7-9f78-0492661407f5" xlink:to="loc_dei_DocumentType_3d8232e3-d5f0-4065-9c98-946e7f91df8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_38d0bd4e-437d-4666-8cd1-f6a73662d2af" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_70e41c6c-71ac-42d7-9f78-0492661407f5" xlink:to="loc_dei_DocumentPeriodEndDate_38d0bd4e-437d-4666-8cd1-f6a73662d2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_0820c4af-3ed5-472f-94d1-335895575390" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_70e41c6c-71ac-42d7-9f78-0492661407f5" xlink:to="loc_dei_EntityRegistrantName_0820c4af-3ed5-472f-94d1-335895575390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_facff44d-a43a-40ab-b296-a9647b5b22f8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_70e41c6c-71ac-42d7-9f78-0492661407f5" xlink:to="loc_dei_EntityIncorporationStateCountryCode_facff44d-a43a-40ab-b296-a9647b5b22f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_c6de0760-bd17-43a5-a310-02c0dbe8739c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_70e41c6c-71ac-42d7-9f78-0492661407f5" xlink:to="loc_dei_EntityFileNumber_c6de0760-bd17-43a5-a310-02c0dbe8739c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_7e69caad-274a-434f-bdf2-86088e2817f6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_70e41c6c-71ac-42d7-9f78-0492661407f5" xlink:to="loc_dei_EntityTaxIdentificationNumber_7e69caad-274a-434f-bdf2-86088e2817f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_be9f7bef-8a5a-4fb3-a119-b33bfe330e87" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_70e41c6c-71ac-42d7-9f78-0492661407f5" xlink:to="loc_dei_EntityAddressAddressLine1_be9f7bef-8a5a-4fb3-a119-b33bfe330e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_582e8a2c-c5c8-4938-8ed0-e5c54e64eeeb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_70e41c6c-71ac-42d7-9f78-0492661407f5" xlink:to="loc_dei_EntityAddressCityOrTown_582e8a2c-c5c8-4938-8ed0-e5c54e64eeeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c24174b9-ef3f-4b5d-96e8-dedea0bffdb9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_70e41c6c-71ac-42d7-9f78-0492661407f5" xlink:to="loc_dei_EntityAddressStateOrProvince_c24174b9-ef3f-4b5d-96e8-dedea0bffdb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_2ad019ba-cd65-446d-926d-08f7e97f4d65" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_70e41c6c-71ac-42d7-9f78-0492661407f5" xlink:to="loc_dei_EntityAddressPostalZipCode_2ad019ba-cd65-446d-926d-08f7e97f4d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a8414376-89a3-43ca-8700-52e99a888936" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_70e41c6c-71ac-42d7-9f78-0492661407f5" xlink:to="loc_dei_CityAreaCode_a8414376-89a3-43ca-8700-52e99a888936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_38351ada-7cc6-41ee-8db7-0bd61ba0db77" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_70e41c6c-71ac-42d7-9f78-0492661407f5" xlink:to="loc_dei_LocalPhoneNumber_38351ada-7cc6-41ee-8db7-0bd61ba0db77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_cd34be20-1f7f-4747-83b6-86cd97c6af39" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_70e41c6c-71ac-42d7-9f78-0492661407f5" xlink:to="loc_dei_WrittenCommunications_cd34be20-1f7f-4747-83b6-86cd97c6af39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_f78d95ec-5bff-41da-a050-cab5f821325f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_70e41c6c-71ac-42d7-9f78-0492661407f5" xlink:to="loc_dei_SolicitingMaterial_f78d95ec-5bff-41da-a050-cab5f821325f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_b3bec193-3026-4dc4-9e1f-8a90d0314a88" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_70e41c6c-71ac-42d7-9f78-0492661407f5" xlink:to="loc_dei_PreCommencementTenderOffer_b3bec193-3026-4dc4-9e1f-8a90d0314a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_f0a9a731-8d84-45d9-9585-e1e2bc777a4a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_70e41c6c-71ac-42d7-9f78-0492661407f5" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_f0a9a731-8d84-45d9-9585-e1e2bc777a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_41c5135b-79d2-40de-826d-c4e449511b2f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_70e41c6c-71ac-42d7-9f78-0492661407f5" xlink:to="loc_dei_Security12bTitle_41c5135b-79d2-40de-826d-c4e449511b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f75880cc-6bae-4980-9022-ac2213cfb5d8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_70e41c6c-71ac-42d7-9f78-0492661407f5" xlink:to="loc_dei_TradingSymbol_f75880cc-6bae-4980-9022-ac2213cfb5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_c63ddea6-6d8b-417c-83f0-915f51221500" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_70e41c6c-71ac-42d7-9f78-0492661407f5" xlink:to="loc_dei_EntityCentralIndexKey_c63ddea6-6d8b-417c-83f0-915f51221500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_28a63923-b378-43cc-a338-025594f2a2d5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_70e41c6c-71ac-42d7-9f78-0492661407f5" xlink:to="loc_dei_EntityEmergingGrowthCompany_28a63923-b378-43cc-a338-025594f2a2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e84c1b5d-9333-406d-86a5-7320d4c74e6e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_70e41c6c-71ac-42d7-9f78-0492661407f5" xlink:to="loc_dei_AmendmentFlag_e84c1b5d-9333-406d-86a5-7320d4c74e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e6caa038-807d-4014-823a-f75f7dad0561" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_70e41c6c-71ac-42d7-9f78-0492661407f5" xlink:to="loc_dei_SecurityExchangeName_e6caa038-807d-4014-823a-f75f7dad0561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>logoa.jpg
<TEXT>
begin 644 logoa.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "? ?$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **3-+0 4444 %%%)F@!:*3-&: %HHHH ***3- "T4E+0 4444 %%%)0 M%)
MFEH **3-+0 4444 %%)FC(H 6BDI: "BBDR* %HHHH **2EH ***2@!:***
M"BBDH 6BBB@ HHHH ***2@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
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M.)^''[27A7XF^*)]#TQKB.Z4,T33( LRKU*UZTO2OSM_9%_Y+7HO_7"7_P!
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M\;8S@CZ5\1_M2?$;_A/OB==0P2[]-TH&T@QT+ _.P^IX_ 5[5^P?QX7\3?\
M7['_ .@&NMT5&GS'QF&SN>)S1X6-N17_  /J44ZFX/>G5R'V@M%%% !1110
M4444 %%%% !1110 4444 %(W2BD9AB@#RW]HKXD+\-_AM?W43A=0NE^S6JYP
M=[<9'T'-?.G[&OPU;Q)XIO/%6H1F2VL<I"SCAYFZG\ :Q/VJ/'D_Q(^*<7A[
M3"T]KITGV2)$Y#W#'#'\#Q^!K["^$'@&'X;^ =+T:-1YT<8>=A_%(1EC^?\
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MIJM.A3;W9V?[(/Q";P;\1)= O6,-IJF8=K'A)U/']17WAVK\]?VDO!4_PO\
MBX^I6"M!;7KB_M77@+)G+ ?CS^-?;/PF\<0_$/P'I6MQ,&>:("8?W9!PP^N?
MYU-:*=IHZ.'ZTJ,JF7U=X/3T.RZUYM\?_B(GPW^&NJ:@CA;V9?L]JN>3(PQG
M\!S^%>D# 6OA3]LCXBMXI\=Q>'K1]]II(VLJG(>9L9_+@5E2AS2/8SK&?4\)
M*4?B>B^9X='H=Y?:'?:XP)M8+A('D;JTCY.!^ .:^M_V#L_\(SXF_P"OR/\
M] -<;\5?AW_PKG]EOP_92IMO[G48[JZ..3(R,<'Z# _"NS_8-_Y%CQ-_U^1_
M^@&NRI+FIMH^'RC"RPN:4XRW<;OYGU,M+2+2UYI^K!1110 4444 %%%% !11
M10 4444 %)2TE #=M>>_'3XB1_#+X<ZGJN\"\9/(M4[M*PPOY=?PKT(U\*?M
M??$.3QM\0[;PQI[F:TTH^643G?<MP1^' _.MJ4>:1X6<8SZGA6U\3T1'^R/X
M$7Q1XZNO%FL,#9:43*9IB-KW#9.23Z<G\J]Y^)'[7'@_P7YMKI<A\1:DF1Y=
MH<1*?]J3I^6:\V^('[/?BW3O@SX;TGPTLD[0[KC5;.&38T\C '/^UMZ8KYE_
MLV;PGKD4>NZ-,1"^9;*XW0E^>F<9%=?+&H[M['P[QF*R>A'#TX6<M7)^9Z;X
MG^-_Q*^-U^VF:=]IBMIC@:?I"$ @]G;J?Q(%<'XT^'NM?#75K.T\26+0/,BS
M^6C@[DSR-PXSVKZN^#/[2'PRL[&'3$TR/P?-@ AT!C8^\@Z_\"K7_:D\%V/Q
M,^&8UW1YH;V[TO\ TB.2W8-OB/WAQ[<_G353EERVL@JY;'&8:6)]O[2HM;'<
M_!/P?X,TOP?IVI^%M,MX8[R!9#<8WRMD<AG//6O25[5\F?L1_$KS8;_P9=R\
MQ9N;/<?X3]]?P//XU]:"N*K>,K,^[RBM2Q&$A.G&W1^IB>.O^1,US_KRF_\
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M'B:68T^CLS]$[JYCL[>6>5@D<:EV)Z  9S7YO^/M6O?CA\:IEM"TGV^[%I;
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ I*6B@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
,* "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 14, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 14,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Adverum Biotechnologies, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-5258327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Cardinal Way<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Redwood City<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">656-9323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADVM<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001501756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    (  B!KEI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    (  B!KEH,Q?]U[P   "L"   1
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M@2";_-;;I/;=X Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F
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MS*/<_LD.'0JM7B037?PEV_VWG8Y#HEP;F1Z"@2#E8G^E;X>!. IH>R<"@D-
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M%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.<V"3J9B+7D%=*RHC_#K3),
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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M/UY_ 5!+ 0(4 Q0    (  B!KEI&QTU(E0   ,T    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ "(&N6@S%_W7O
M*P(  !$              ( !PP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ "(&N6IE<G",0!@  G"<  !,              ( !X0$  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    "  (@:Y:D<^';C4$  !H$   &
M            @($B"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ "(&N6I^@&_"Q @  X@P   T              ( !C0P  'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    "  (@:Y:EXJ[',     3 @  "P
M    @ %I#P  7W)E;',O+G)E;'-02P$"% ,4    "  (@:Y:JL0B%C,!   B
M @  #P              @ %2$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ "(&N6B0>FZ*M    ^ $  !H              ( !LA$  'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ "(&N6F60>9(9 0  SP,
M !,              ( !EQ(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/  D "0 ^ @  X1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="advm-20250514.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="advm-20250514.htm">advm-20250514.htm</File>
    <File>advm-20250514.xsd</File>
    <File>advm-20250514_lab.xml</File>
    <File>advm-20250514_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "advm-20250514.htm": {
   "nsprefix": "advm",
   "nsuri": "http://www.adverum.com/20250514",
   "dts": {
    "inline": {
     "local": [
      "advm-20250514.htm"
     ]
    },
    "schema": {
     "local": [
      "advm-20250514.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "advm-20250514_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "advm-20250514_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 24
   },
   "report": {
    "R1": {
     "role": "http://www.adverum.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20250514.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20250514.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001628280-25-025486-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-25-025486-xbrl.zip
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MG@;$#^D (3'>. 45\U'-/@7TMD2X?U+J:999:O9HD+#C\@*@+>">A8#&I 6
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M.=C1_'HDGNO5=8:@MX[E9KQ8:GAAG^O K)+6IPZQ;$.'B45;>:^!'==1P#W
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MMWWE3]Z]]>682?_7%[+G-T6GW6UU^@._W>_4^:#3:#0'[7ZST6GL^_W_:[R
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M/NLG<AE%&C=1I+X/%#GR 5=9R/XA52J\403;#:70[%S$*DDU>R\3G;(_,IX
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M%@<\0E?G\PC]M]:LGB5M:D3;L(LH.&*9B@4!/A'@0,%GP$*XH77PYSQZ=#+
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ME+!M*<A-N*A8VYT4W*47AH8^QGX%FZT"E8GN.,4(P%WLV*C+4\L0L(3I"_H
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M-+VQ55>\+Q4E@,$9U,4J3OY5D4(T'77V>?$8P-,*PDQ,J :F!5?IU+:"YDN
MJ( -X+E\4?6 4U*UW(X' ?,Q,*>V=3Q^[N],0^"R+ZGR+FT/$W631MKD >UB
M-OHW$4QR([HPZ/FIX3;GT+]XC&%7BGRJI<AM4GC_I!2,36!6\D)CL0TJK]%S
M.S^N\EIN=S65MPHR"#"K;Z;5WH![,@#!$J5RJRB:F$]('<#[/HZ, *,*QED
MT7_>M_81>]/8,4]48!K312BK&A+S%R:5@?,J(AECUWI5LRW2A,L4X:N7G=ZA
MZ1(S6='!0(L4(8508KF^75,K#E?!J-&+>S^J%W>ROZ;L?P1Z!TIOQ!LW5&_O
MN_6<[ X#LO_4="$>!MYCP&!8QT5C*M%&H;<,(NW<6@TT]TN7W^P%/'?M7M<K
MBV<59A_U59966W&_+9EO>%@NRN,M*K:0RT7C6M\5A&6*R@A:)0IX8*RHJ;QH
M90'*AB()<,K4CDD!BP!'XO1KK=YLOG%,[#8] SLU^)%/8GG -U1^K+!F/G"
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M4$L! A0#%     @ "(&N6@%%'BA? @  ]@8  !$              ( !:0\
M &%D=FTM,C R-3 U,30N>'-D4$L! A0#%     @ "(&N6L,.SV<("@  ?50
M !4              ( !]Q$  &%D=FTM,C R-3 U,31?;&%B+GAM;%!+ 0(4
M Q0    (  B!KEKYS3FKJP8  -PP   5              "  3(<  !A9'9M
M+3(P,C4P-3$T7W!R92YX;6Q02P$"% ,4    "  (@:Y:>R8WX@D;  !;U
M'@              @ $0(P  97AH:6)I=#DY,5\U,30R-7!R97-S<F5L96$N
9:'1M4$L%!@     %  4 4 $  %4^      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>advm-20250514_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="advm-20250514.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2025-05-14</startDate>
            <endDate>2025-05-14</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="c-1" id="f-21">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001501756</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-05-14</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Adverum Biotechnologies, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-36579</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">20-5258327</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">100 Cardinal Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Redwood City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">94063</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">656-9323</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">ADVM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-23">2025-05-14</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-24">2025-05-14</dei:DocumentPeriodEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
